|
Sumatriptan: In the Treatment of Migraine from Bench to Bed Side
|
|
| Author:
|
NISHU SINGLA
|
| Abstract:
|
Among the episodic neurological disorder, migraine disorder is the most common disorder. During a migraine attack, pulsations occur only in one area of the head. Migraine is caused by vasodilation and activation of perivascular afferent terminals of the trigeminal nerve. Traditional symptoms-based therapies has limited accomplishment and efficacy in treating the disorders. Recently, sumatriptan emerged as novel triptan capable of improving symptoms in patients suffering from migraine. In the Netherlands in 1991, sumatriptan was first available clinically and became available in the USA during 1993. The anti-migraine action of sumatriptan is mediated primarily by vasoconstriction rather than by neuronal inhibition. Sumatriptan having structuraly similarity to serotonin (5HT) and is 5 -HT receptor (types 5- HT1D and 5-HT1B) agonist. Sumatriptan seems to be effective against all features of the headache phase of migraine attacks, according to clinical trials data. Sumatriptan is produced and marketed as a combination product with naproxen. In this review, we have collected and presented all the data on sumatriptan treating migraine including status of recent clinical trials on sumatriptan alone or in combination with other adjuvant therapies for migraine.
|
| Keyword:
|
Migraine, Sumatriptan, Disorder, Symptoms, Receptor
|
| EOI:
|
-
|
| DOI:
|
https://doi.org/10.31838/ijpr/2020.SP3.053
|
| Download:
|
Request For Article
|
|
|